VISHEE(SH:688580)2023-04-25 16:00Dividend Distribution - The company plans to distribute a cash dividend of RMB 6.876 per 10 shares, totaling approximately RMB 46.91 million, based on a total share capital of 68,222,419 shares after buybacks[5]. - The total cash dividend for 2022 amounts to RMB 61.77 million, representing 65.83% of the net profit attributable to shareholders[6]. - The company has repurchased shares worth RMB 14.86 million during the year, which is included in the cash dividend calculation[6]. - The company does not plan to increase capital reserves or issue bonus shares, with remaining undistributed profits carried forward[5]. Financial Performance - The company's operating revenue for 2022 was CNY 321,621,418.85, a decrease of 25.21% compared to CNY 430,044,459.65 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 93,825,897.99, down 47.23% from CNY 177,811,885.55 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 76,590,650.79, a decline of 48.99% from CNY 150,144,023.66 in 2021[25]. - The cash flow from operating activities for 2022 was CNY 86,168,338.86, down 45.24% from CNY 157,367,012.60 in 2021[25]. - The basic earnings per share for 2022 was CNY 1.3739, a decrease of 47.19% compared to CNY 2.6016 in 2021[26]. - The total assets at the end of 2022 were CNY 1,684,216,383.26, an increase of 2.77% from CNY 1,638,742,744.28 at the end of 2021[25]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,528,547,226.43, a slight decrease of 0.29% from CNY 1,533,062,870.88 at the end of 2021[25]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 19.07% in 2022, up 4.30 percentage points from 14.77% in 2021[26]. - The company submitted 98 patent applications during the reporting period, with 95 patents granted, including 24 invention patents[36]. - The company has developed a compact high-voltage medical power supply for magnetic stimulation products, achieving a continuous output of 100Hz pulse frequency and 6Tesla magnetic field strength[83]. - The company has filed for 40 invention patents in the rehabilitation robotics field, with products covering lower and upper limb rehabilitation training expected to be fully launched in 2022[85]. - The company is actively researching functional electrical stimulation and intelligent electrical stimulation technologies to enhance rehabilitation capabilities[89]. Market Expansion and Strategy - Future outlook includes expanding product lines in pelvic floor rehabilitation and cognitive function recovery, targeting a market growth of 15% annually[15]. - Market expansion strategies involve entering Southeast Asian markets, aiming for a 10% market share within two years[15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in robotic rehabilitation technologies[15]. - The company aims to improve operational efficiency by reducing production costs by 8% through automation and process optimization[15]. - The company is focusing on the medical aesthetics energy source market, with a diverse product matrix covering gynecology, dermatology, and medical beauty, targeting to become a top brand in China's medical aesthetics energy source market[45]. Operational Risks and Compliance - The company has faced various operational risks, which are detailed in the report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has received a standard unqualified audit report from Tianheng Accounting Firm[5]. - The company’s board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company is actively monitoring industry policies and regulations to adapt its strategic layout in response to potential risks[120]. Talent and Management - The company has implemented a talent incentive mechanism, including an "Elite Talent Program" and stock incentive plans, to enhance team stability and cohesion[46]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 700.75 million[200]. - The company is implementing a talent cultivation program to develop management and specialized personnel, enhancing overall human resource quality[176]. - The company has seen personnel changes, with three executives resigning due to personal reasons, including the Deputy General Manager and Chief Technology Officer[199]. Product Development and Innovation - The company is focusing on rehabilitation medical devices utilizing electrical stimulation, electrophysiology, and magnetic stimulation technologies[14]. - The introduction of the MyOnyx series, a new line of biofeedback devices, is expected to generate $2 million in revenue within the first year of launch[15]. - The company achieved a significant milestone by being recognized as a national-level specialized and innovative "little giant" enterprise in 2022[91]. - The company is developing next-generation magnetic stimulation products aimed at various medical applications, including obstetrics and rehabilitation[98]. Financial Guidance and Future Outlook - The financial guidance for the next quarter anticipates a revenue increase of 20% year-over-year, driven by new product launches and market expansion[15]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $625 million[194]. - The company plans to enhance its research and development capabilities, targeting high-end and high-growth markets, and aims to achieve breakthroughs in technologies such as electrical stimulation and rehabilitation robotics[170].